GlassScriptPhysician profile
Jeffrey I Brown
NPI 1730159310
$13,517.99
in general payments reported to CMS, 2019-2025
35 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $1,488 · 2021: $2,604 · 2022: $2,365 · 2023: $2,628 · 2024: $2,294 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,348 · Education: $20.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,348.07 |
| Education | $20.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,185.83 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,878.48 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,672.82 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,325.25 | 2019-2025 | Stelara, Simponi, Remicade |
| Pfizer INC. | $473.83 | 2019-2025 | |
| Celgene Corporation | $470.08 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $448.88 | 2021-2023 | |
| Ardelyx, INC. | $299.51 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $256.82 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $228.83 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $220.19 | 2020-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $219.41 | 2019-2024 | Rebyota |
| Ironwood Pharmaceuticals, INC | $201.98 | 2020-2024 | Linzess |
| Daiichi Sankyo INC. | $152.76 | 2019-2023 | Injectafer |
| Ucb, INC. | $147.21 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $142.93 | 2023-2024 | Dupixent |
| Genzyme Corporation | $126.27 | 2023-2024 | |
| Lilly USA, LLC | $119.65 | 2024-2025 | Omvoh |
| Astrazeneca Pharmaceuticals LP | $114.35 | 2019 | |
| Gilead Sciences, INC. | $101.22 | 2023-2025 | |
| Amgen INC. | $91.65 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $89.58 | 2024-2025 | Zenpep |
| Fresenius Kabi USA, LLC | $85.35 | 2023-2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $77.10 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.93 | 2023 | Cyltezo |
| Vivus LLC | $48.62 | 2021-2022 | |
| Madrigal Pharmaceuticals | $45.11 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $41.80 | 2020-2021 | |
| Shionogi INC | $39.01 | 2019 | |
| Braintree Laboratories, INC. | $38.28 | 2024 | Suflave, Sutab |
| Romark Laboratories, Lc | $36.49 | 2020 | |
| Phathom Pharmaceuticals, INC. | $30.14 | 2024 | Voquezna |
| Celltrion USA INC. | $20.99 | 2024 | Zymfentra |
| Echosens North America, INC. | $13.52 | 2024 | Fibroscan |
| Evoke Pharma, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.